Please assess the completion status of the following clinical trial:

Trial Title: Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of invasive or in situ epithelial cancer of the breast~  * Stage 0, I, or II (Tis, T1, or T2) disease~ * Unifocal disease (single focus that can be encompassed by breast-conserving surgery)~* Has undergone prior surgical resection of the primary lesion (lumpectomy) and axillary nodal evaluation (if invasive disease is present)~  * Negative surgical margins (≥ 1 mm)~* Planning to undergo radiotherapy with either standard external beam radiotherapy or accelerated partial breast irradiation (interstitial or balloon brachytherapy)~* No Paget disease of the nipple~* No evidence of distant metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Karnofsky performance status 70-100%~* Transaminases \< 3 times upper limit of normal (ULN)~* Creatine kinase \< 5 times ULN~* Creatinine clearance ≥ 30 mL/min~* Negative pregnancy test~* No active liver or muscle disease~* No history of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis)~* History of prior malignancy allowed provided life expectancy is ≥ 4 years~* No major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of study treatment or interfere with follow-up~* No contraindication to an HMG-coA-reductase inhibitor~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiotherapy to the breast, lung, or mediastinum~  * Prior radiotherapy to the contralateral breast allowed~* No chemotherapy for ≥ 2 weeks prior to, during, and for ≥ 2 weeks after completion of radiotherapy~* No concurrent cytochrome P450 3A4 inhibitors~* Concurrent HMG-coA-reductase inhibitor allowed provided patient is able to switch to 20 mg of lovastatin per day~* Concurrent tamoxifen or an aromatase inhibitor allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (lovastatin) (Type: EXPERIMENTAL): Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).